Rituxan (rituximab), a new monoclonal antibody for cancer

Hoffmann-La Roche is now marketing Rituxan (rituximab), a new monoclonal antibody for cancer.

Rituxan is for certain cases of non-Hodgkin's lymphoma (NHL).

Rituxan binds to the malignant antibody-producing B-cells...this helps the immune system to recognize and eliminate them.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote